AVITA Medical, Inc. (AVHHL)
AVHHL is quoted over the counter, not listed on an exchange. AVITA Medical, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | AVHHL, quoted over the counter |
| SEC CIK | 0001762303 |
| OTC Markets tier | Pink (price source, 2026-11-13) |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Business address | Valencia, CA |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As of December 31, 2025, as a result of the prior conclusion that there was substantial doubt about the Company's ability to continue as a going concern and the Company's debt service obligations, the long-term portion of the credit facility was classified as a current liability in the accompanying Consolidated Balance Sheet . 2." | 10-Q 2026-11-05 |
| Cash and burn | $10.5M cash; operating cash flow -$4.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 31,420,219 (2026-11-03); 30,493,111 a year earlier; 25,550,694 three years earlier. | Cover page 2026-11-03 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-06-08 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Grant Thornton LLP, Newport Beach, California, United States | PCAOB Form AP 2026-03-07 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $235K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $26.1M | -$6.2M | -$710K | $10.5M | $45.5M | $84.7M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $21.7M | -$7.7M | -$3.5M | $9.1M | $46.7M | $75.6M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $19.3M | -$10.6M | -$10.1M | $8.3M | $46.1M | $72.3M | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $17.6M | -$11.6M | -$5.4M | $10.2M | $43.0M | $71.6M | 10-K 2026-02-12 |
| Q3 2025 2025-09-30 | $17.1M | -$13.2M | -$5.2M | $15.4M | $42.4M | $72.4M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $18.4M | -$9.9M | -$10.2M | $12.2M | $42.2M | $74.9M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $18.5M | -$13.9M | -$10.3M | $14.9M | $41.5M | $71.7M | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | $18.4M | -$11.6M | -$8.0M | $14.1M | $42.2M | $64.3M | 10-K 2026-02-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-06-08 |
| Latest annual report | 10-K | 2026-02-12 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEF 14A | 2026-04-22 |
Source: SEC EDGAR submissions feed, 379 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier